



## Radiopharmaceuticals: From Design to Applications

Guest Editor:

### **Dr. Aristeidis Chiotellis**

National Center for Scientific  
Research “Demokritos”, Institute  
of Nuclear & Radiological  
Sciences & Technology, Energy &  
Safety, Agia Paraskevi, 15341  
Athens, Greece

Deadline for manuscript  
submissions:

**closed (31 March 2023)**

### **Message from the Guest Editor**

Radiopharmaceuticals play a pivotal role in nuclear medicine, where they are widely used as diagnostic and therapeutic agents with their most important applications found in the understanding of neurodegenerative diseases, myocardial imaging, and the diagnosis and treatment of cancer.

For the potential impact of nuclear medicine in patient management and personalized medicine to be fully realized, there remains an urgent need to develop new radiopharmaceuticals for molecular targets of disease relevance that are not currently addressed while exhibiting optimal *in vivo* performance. Nevertheless, the development of the “ideal” radiopharmaceutical is challenging since a plethora of issues need to be addressed such as selectivity and specificity for the molecular target in question, feasible chemistry for clinical applications, and optimal pharmacokinetic characteristics.

This Special Issue is dedicated to all efforts towards the development of target-specific radiopharmaceuticals aiming to address unmet clinical needs, as well as novel methodologies for the design and development of more effective radiopharmaceuticals with optimal *in vivo* performance.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceutics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma